 | This article needs to be updated. Please help update this article to reflect recent events or newly available information. (October 2021) |
 Share of population in Kazakhstan that has received at least one dose of COVID-19 vaccine by region as of 29 July 2022 | |
| Date | 1 February 2021 (2021-02-01) – present |
|---|---|
| Location | Kazakhstan |
| Cause | COVID-19 pandemic in Kazakhstan |
.svg){kind=small}
COVID-19 vaccination in Kazakhstan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Background
Shortly after the COVID-19 outbreak in Kazakhstan, Erlan Ramanqūlov, the Director General of the National Center for Biotechnology announced in April 2020 the stages on developing the COVID-19 vaccine, acknowledging that clinical trials usually take up to 10 years to develop and that all verified research process would be cut short due to the intense situation in the country, expediting the coronavirus vaccine production and forecasted that it would be available to the public within the next year and a half.
On 18 May 2020, the Ministry of Education and Science announced that the preclinical trials for the local COVID-19 vaccine had begun of which was developed by the employees of the Research Institute of Biological Safety Problems of the Science Committee (BQPĞZÏ) under the Ministry by the strain of the coronavirus isolated from patients and that the World Health Organization (WHO) had registered the vaccine development. At the cabinet meeting, Education and Science Minister Ashat Aimagambetov announced that five COVID-19 vaccines were being developed and that the preclinical trials would be tested on animals until September 2020, when the clinical stages would begin for humans. In August 2020, the National Center for Expertise of Medicines and Medical Devices reported that the QazCovid-in vaccine showed no dangers during preclinical study stage and ruled that the testing could advance further into clinical trials on humans. Starting 1 September 2020, the BQPĞZI began recruiting volunteers for conducting clinical trials of QazCovid-in. In December 2020, the Ministry of Healthcare approved the final phase III of clinical trials by the BQPĞZI for 3,000 volunteers, by which the institute reported 96% efficiency rate of QazCovid-in.
Kazakhstan has created its own COVID-19 vaccination, QazCovid-in, developed by the Research Institute for Biological Safety Problems. On 7 April 2021, the Healthcare Minister Alexey Tsoi announced that the Kazakh government had requested 4 million doses of Russia's Sputnik V vaccine, in addition to 2 million doses already received earlier in 2021, as part of an ongoing vaccination programme alongside QazCovid-in.
In October 2021, the first Kazakh vaccine to protect cats from COVID-19, NARUVAX-C19, was unveiled at the Kazagro/Kazfarm-2021 international exhibition.
Vaccine in order
| Vaccine | Approval | Deployment |
|---|---|---|
| Sputnik V |  Yes
|
Yes
|
| QazCovid-in | Yes
|
Yes
|
| Sinopharm BIBP | Yes
|
Yes
|
| Sinovac | Yes
|
Yes
|
| Sputnik Light | Yes
|
 No
|
| QazCoVac-P | No
|
No
|
Vaccination rate by region
| Region | Vaccinated population (as of 29 July 2022) | |||||
|---|---|---|---|---|---|---|
| Amount | Percentage | |||||
| 1st dose | 2nd dose | Booster dose | 1st dose | 2nd dose | Booster dose | |
| Akmola Region | 376,526 | 363,785 | 51.3% | 49.6% | ||
| Aktobe Region | 442,646 | 435,541 | 48.6% | 47.8% | ||
| Almaty Region | 1,183,805 | 1,130,834 | 55.9% | 53.4% | ||
| Atyrau Region | 292,152 | 276,467 | 43.4% | 41.1% | ||
| East Kazakhstan Region | 1,032,215 | 1,025,710 | 76.2% | 75.7% | ||
| Jambyl Region | 772,156 | 762,453 | 67.0% | 66.1% | ||
| Karaganda Region | 726,370 | 678,609 | 53.0% | 49.5% | ||
| Kostanay Region | 380,772 | 367,483 | 44.5% | 42.9% | ||
| Kyzylorda Region | 516,071 | 510,599 | 62.0% | 61.4% | ||
| Mangystau Region | 279,861 | 272,261 | 37.3% | 36.3% | ||
| Pavlodar Region | 385,060 | 375,954 | 51.6% | 50.4% | ||
| North Kazakhstan Region | 342,656 | 338,133 | 64.1% | 63.3% | ||
| Turkistan Region | 1,294,982 | 1,290,145 | 62.0% | 61.8% | ||
| West Kazakhstan Region | 297,268 | 287,561 | 44.5% | 43.1% | ||
| Almaty | 1,211,479 | 1,186,646 | 59.1% | 57.9% | ||
| Nur-Sultan | 542,653 | 516,130 | 43.0% | 40.9% | ||
| Shymkent | 707,126 | 696,298 | 62.9% | 61.9% | ||
 Kazakhstan
|
10,783,798 | 10,514,609 | 5,012,630 | 57.5% | 56.1% | 26.7% |
| Total doses: | 26,311,037 | |||||
References
- "Названы сроки создания вакцины против COVID-19 в Казахстане - Новости Казахстана и мира на сегодня". 24.kz (in Russian). April 17, 2020. Archived from the original on July 15, 2021. Retrieved July 15, 2021.
- "В Казахстане начали доклинические испытания вакцины от коронавируса - Аналитический интернет-журнал Vласть". vlast.kz (in Russian). May 18, 2020. Archived from the original on May 26, 2020. Retrieved July 15, 2021.
- Дубовая, Мария (June 19, 2020). "Испытания казахстанской вакцины против коронавируса на людях планируют начать в сентябре". informburo.kz (in Russian). Archived from the original on July 24, 2020. Retrieved July 15, 2021.
- "Казахстанская вакцина от COVID-19 может быть применена на людях-добровольцах – НЦЭЛС". KazTAG (in Russian). August 19, 2020. Archived from the original on July 14, 2023. Retrieved July 14, 2023.
- "THE RECEPTION OF QUESTIONNAIRES OF VOLUNTEERS TO PARTICIPATE IN CLINICAL TRIALS OF THE KAZAKHSTANI QAZCOVID-IN®-COVID-19 INACTIVATED VACCINE, DEVELOPED AT RIBSP HAS BEGUN" (Press release). Research Institute for Biological Safety Problems. September 1, 2020. Archived from the original on July 14, 2023. Retrieved July 14, 2023.
- "Kazakhstan starts vaccination of three thousand volunteers with domestic QazCovid-in vaccine". primeminister.kz. December 19, 2020. Archived from the original on July 14, 2023. Retrieved July 14, 2023.
- Yergaliyeva, Aidana (December 20, 2020). "Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in". The Astana Times. Archived from the original on December 28, 2020. Retrieved April 7, 2021.
- "Kazakhstan asks Russia for additional Sputnik V supplies". Reuters. April 7, 2021. Archived from the original on May 11, 2021. Retrieved April 7, 2021.
- October 2021, Saniya Bulatkulova in Society on 25 (October 25, 2021). "No Pet Left Behind! New NARUVAX-C19 Vaccine for Cats Unveiled in Nur-Sultan". The Astana Times. Archived from the original on December 8, 2021. Retrieved December 8, 2021.
{{cite web}}: CS1 maint: numeric names: authors list (link) - Satubaldina, Assel (April 30, 2021). "Three Vaccines to Become Available to Kazakh Citizens". The Astana Times. Archived from the original on April 30, 2021. Retrieved May 1, 2021.
- "В Казахстан доставили первую партию китайской вакцины CoronaVac | Kazakhstan Today". www.kt.kz (in Russian). Archived from the original on June 7, 2021. Retrieved June 7, 2021.
- "Kazakhstan approves Russia's single-dose Sputnik Light vaccine". Reuters. Moscow. July 15, 2021. Archived from the original on July 15, 2021. Retrieved July 15, 2021.
- "Информация о проведении вакцинации населения против КВИ на 29.07.2022 г. в разрезе регионов". gurk.kz (in Russian). МЕДИА-ЦЕНТР МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РК. July 29, 2022. Archived from the original on July 30, 2022. Retrieved July 30, 2022.
| COVID-19 vaccination in Europe | |
|---|---|
| Sovereign states |
|
| States with limited recognition | |
| Dependencies and other entities | |
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Misplaced Pages by expanding it. |
 | This Kazakhstan-related article is a stub. You can help Misplaced Pages by expanding it. |